/BGLC
BGLC Stock - BioNexus Gene Lab Corp.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$4.23+2.42%
+$0.10 (+2.42%) • Dec 19
49
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.32
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.31
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $4.65
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BGLC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.19 – $4.27
TARGET (TP)$4.86
STOP LOSS$3.89
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.21
52W High$15.60
52W Low$2.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.51M | $9.77M | $10.93M | $13.36M | $11.39M |
| Gross Profit | $1.29M | $1.33M | $1.26M | $2.19M | $1.72M |
| Gross Margin | 13.6% | 13.6% | 11.5% | 16.4% | 15.1% |
| Operating Income | $-1,573,702 | $-2,593,588 | $-291,177 | $1.06M | $1.27M |
| Net Income | $-1,598,342 | $-2,629,043 | $-355,966 | $751,571 | $1.09M |
| Net Margin | -16.8% | -26.9% | -3.3% | 5.6% | 9.6% |
| EPS | $-0.90 | $-1.53 | $-0.25 | $0.53 | $1.28 |
Company Overview
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BGLCBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.39
Q4 2025
EPS Surprise History
Q2 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q2 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-0.39 | — | — |
Q3 2025 | Aug 18, 2025 | — | $-0.34 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.03 | — | — |
Q2 2025 | Apr 15, 2025 | — | $-0.19 | — | — |
Q4 2024 | Nov 15, 2024 | — | $-0.20 | — | — |
Q3 2024 | Aug 14, 2024 | — | $0.10 | — | — |
Q2 2024 | May 31, 2024 | — | $-0.18 | — | — |
Q2 2024 | May 31, 2024 | — | $-0.11 | — | — |
Q2 2024 | May 31, 2024 | — | $-0.05 | — | — |
Q2 2024 | May 15, 2024 | — | $-0.18 | — | — |
Q1 2024 | Mar 29, 2024 | — | $0.17 | — | — |
Q4 2023 | Nov 20, 2023 | — | $-0.20 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-0.05 | — | — |
Q3 2022 | Aug 15, 2022 | — | $-0.10 | — | — |
Q2 2022 | May 16, 2022 | — | $0.01 | — | — |
Q2 2022 | Apr 6, 2022 | — | $0.06 | — | — |
Q4 2021 | Nov 15, 2021 | — | $0.21 | — | — |
Q3 2021 | Aug 12, 2021 | — | $0.02 | — | — |
Q2 2021 | May 18, 2021 | — | $0.24 | — | — |
Q1 2021 | Mar 30, 2021 | — | $1.47 | — | — |
Latest News
BioNexus Gene Lab Corp Secures$500M Equity Facility From ARC Group
📈 PositiveBenzinga•Dec 2, 2025, 01:33 PM•Also:
BioNexus Gene Lab Executes Intellectual Property License Agreement For Southeast Asia With Fidelion Diagnostics For VitaGuard Minimal Residual Disease Liquid Biopsy Platform
📈 PositiveBenzinga•Dec 1, 2025, 01:07 PM
BioNexus Enters Into Definitive Agreements With Fidelion And Tongshu To Commercialize VitaGuard, Tumor-Naïve Liquid-Biopsy Platform For Minimal Residual Disease
📈 PositiveBenzinga•Nov 12, 2025, 01:06 PM
BioNexus Gene Lab Files $100M Shelf Registration And Establishes $20M ATM Program To Support Growth In Precision Oncology And Gene-Based Technologies
📈 PositiveBenzinga•Nov 10, 2025, 01:16 PM
BioNexus Gene Lab Files For Mixed Shelf Of Up To $100M
➖ NeutralBenzinga•Nov 7, 2025, 09:37 PM
BGLC stock has given up its prior gain. BioNexus Gene shares were trading higher after the company announced a partnership with BirchBioMed to lead its $10 million funding round through an equity investment and collaboration.
➖ NeutralBenzinga•Oct 20, 2025, 12:47 PM
BioNexus Gene shares are trading higher after the company announced a partnership with BirchBioMed to lead its $10 million funding round through an equity investment and collaboration.
📈 PositiveBenzinga•Oct 20, 2025, 12:03 PM
BioNexus Gene Enters Partnership With BirchBioMed To Lead Birch's $10M Funding Round Through Equity Investment, Collaboration
📈 PositiveBenzinga•Oct 20, 2025, 12:01 PM
Frequently Asked Questions about BGLC
What is BGLC's current stock price?
BioNexus Gene Lab Corp. (BGLC) is currently trading at $4.23 per share. The stock has moved +2.42% today.
What is the analyst price target for BGLC?
No analyst price targets are currently available for this stock.
What sector is BioNexus Gene Lab Corp. in?
BioNexus Gene Lab Corp. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is BGLC's market cap?
BioNexus Gene Lab Corp. has a market capitalization of $0.01 billion, making it a small-cap company.
Does BGLC pay dividends?
No, BioNexus Gene Lab Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADVB
Advanced Biomed Inc. Common Stock
$0.36
Mkt Cap: $0.0B
AEON
AEON Biopharma, Inc.
$1.08
Mkt Cap: $0.0B
APM
Aptorum Group Limited
$1.13
Mkt Cap: $0.0B
CHEK
Check-Cap Ltd.
$1.61
Mkt Cap: $0.0B
GLTO
Galecto, Inc.
$27.17
Mkt Cap: $0.0B
LFWD
Lifeward Ltd.
$0.65
Mkt Cap: $0.0B
LYRA
Lyra Therapeutics, Inc.
$3.60
Mkt Cap: $0.0B
MBIO
Mustang Bio, Inc.
$1.09
Mkt Cap: $0.0B
TRIB
Trinity Biotech plc
$0.90
Mkt Cap: $0.0B
XAIR
Beyond Air, Inc.
$0.91
Mkt Cap: $0.0B
Explore stocks similar to BGLC for comparison